Educational course on Graft-versus-Host-Disease: the status quo of GvHD management

The Goal

To make a layered exploration of both acute & chronic GvHD, to provide latest trends on the use of combination therapies in the treatment of GvHD, and to share data on the benefits of ECP in the early stages of the treatment pathway for SR-aGvHD as well as how to improve the overall survival in aGvHD by applying ECP.

Agenda

Download Agenda PDF

Day 1 - 11 December 2025

09:00 – 09:15
Welcome and introduction - Prof Robert Zeiser & Therakos Healthcare Stakeholder Engagement Department

09:15 – 09:30
New MDR approved indications for the Therakos Cellex System - Therakos Medcial Affairs

09:30 – 09:50
ECP as a tolerogenic therapy – The Mechanism of Action - Prof Robert Zeiser

09:50 – 10:10
Acute GvHD: Benefits of ECP in the early stages of the treatment pathway for SR-aGvHD - Prof Robert Zeiser

10:10 – 10:20
Interactive discussion - All

10:20 – 10:30
Coffee Break

10:30 – 10:50
Acute GvHD: How to improve overall survival in aGvHD by applying ECP - Prof Daniele Avenoso

10:50 – 11:10
Acute GvHD: Combination therapy in SR-aGvHD - Prof Nicolaus Kroger

11:10 – 11:30
Interactive discussion - All

11:30 – 12:00
Chronic GvHD: cGvHD therapeutic options in a changing therapeutic landscape – Optimizing treatment approach - Prof Hildegard Greinix

12:00 – 13:00
Lunch

13:00 – 13:30
Chronic GvHD: Managing cGvHD with combination therapy - Prof Robert Zeiser

13:30 – 14:00
Chronic GvHD: ECP vs Ruxolitinib: a focus on organ-specific response - Dr. Med Kristina Mass-Bauer

14:00 – 14:30
Interactive discussion - All

14:30 – 15:15
Patient cases discussion - All

15:15 – 15:30
Final remarks and close - Prof Robert Zeiser

For this course, participants are required to submit one patient case for discussion 15 days in advance of the session.

GvHD: Graft Versus Host Disease ECP: Extracorporeal Photopheresis SR: Steroid Refractory

All speakers are subject to contract.
This information is intended for healthcare professionals based in Europe.

Hosted by

Prof Robert Zeiser

University Hospital Freiburg, Germany

Prof Nicolaus Kröger

University Medical Center Hamburg-Eppendorf, Germany

Dr. Med Kristina Mass-Bauer

University of Freiburg, Germany

Prof Daniele Avenoso

Università degli Studi di Brescia, Spedali Civili di Brescia, Italy

Prof Dr Hildegard Greinix

President, Worldwide Network for Blood & Marrow Transplantation (WBMT), Medical University of Vienna

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd.

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.